Pettinga Financial Advisors, LLC Abb Vie Inc. Transaction History

Pettinga Financial Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	SELL	$137.62 - $174.96 $176,428 - $224,298	-1,282 Closed	0 $0
Q1 2022 Apr 27, 2022	BUY	$131.98 - $163.75 $169,198 - $209,927	1,282 New	1,282 $208,000
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $235,486 - $297,958	-2,192 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$106.4 - $120.78 $18,513 - $21,015	174 Added 8.62%	2,192 $236,000
Q1 2021 Apr 29, 2021	SELL	$102.3 - $112.62 $25,575 - $28,155	-250 Reduced 11.02%	2,018 $218,000
Q4 2020 Jan 29, 2021	BUY	$80.49 - $108.67 $182,551 - $246,463	2,268 New	2,268 $243,000
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $194,843 - $228,682	-2,268 Closed	0 $0
Q2 2020 Jul 22, 2020	BUY	$73.37 - $98.18 $166,403 - $222,672	2,268 New	2,268 $223,000
Q1 2020 May 11, 2020	SELL	$64.5 - $97.79 $149,769 - $227,068	-2,322 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $167,485 - $209,560	2,322 New	2,322 $206,000
Q1 2019 May 13, 2019	SELL	$77.14 - $90.79 $186,833 - $219,893	-2,422 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$77.85 - $96.01 $188,552 - $232,536	2,422 New	2,422 $223,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Pettinga Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Pettinga Financial Advisors, LLC with notifications on news.